Insilico Medicine recorded a substantial market gain following its Hong Kong listing, according to a BioCentury finance report. The listing outcome boosted Insilico’s public valuation and highlighted investor appetite for AI‑driven drug discovery companies that transitioned to public markets in late 2025. BioCentury’s summary placed the Insilico move in the context of broader capital flows into computational biology and radiopharma IPO interest, noting the company’s improved financing position post‑listing and the wider implications for AI‑first biotech firms seeking public funding.